Hair loss and drugs of ingredients of imiquimod - a phase IV clinical study of FDA data


Summary:

Hair loss is found among people who take drugs with ingredients of imiquimod, especially for people who are female, 60+ old , have been taking the drugs for 1 - 6 months. This phase IV clinical study is created by eHealthMe based on reports of 4,479 people who have side effects when taking drugs with ingredients of imiquimod from the FDA, and is updated regularly.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Aldara, Imiquimod, Zyclara.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.


On Mar, 20, 2023

4,479 people reported to have side effects when taking drugs with ingredients of imiquimod.
Among them, 66 people (1.47%) have Hair loss


What is Hair loss?

Hair loss is found to be associated with 3,889 drugs and 3,358 conditions by eHealthMe.

Number of reports submitted per year:

Could drugs with ingredients of imiquimod cause Hair loss?

Time on drugs with ingredients of imiquimod when people have Hair loss *:

  • < 1 month: 40 %
  • 1 - 6 months: 60 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Hair loss when taking drugs with ingredients of imiquimod *:

  • female: 80 %
  • male: 20 %

Age of people who have Hair loss when taking drugs with ingredients of imiquimod *:

  • 0-1: 0.0 %
  • 2-9: 3.7 %
  • 10-19: 1.85 %
  • 20-29: 31.48 %
  • 30-39: 7.41 %
  • 40-49: 7.41 %
  • 50-59: 5.5600000000000005 %
  • 60+: 42.59 %

Conditions people have *:

  1. Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 18 people, 27.27%
  2. Squamous Cell Carcinoma (a cancer of a kind of epithelial cell): 4 people, 6.06%
  3. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 6.06%
  4. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 4.55%
  5. Depression: 2 people, 3.03%
  6. Skin Cancer: 2 people, 3.03%
  7. Precancerous Skin Lesion: 2 people, 3.03%
  8. Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 2 people, 3.03%
  9. Carcinoid Tumor: 2 people, 3.03%
  10. Immunodeficiency Disorders: 2 people, 3.03%

Other drugs people take *:

  1. Zyrtec: 20 people, 30.30%
  2. Doxycycline: 19 people, 28.79%
  3. Neulasta: 19 people, 28.79%
  4. Zantac: 18 people, 27.27%
  5. Elidel: 18 people, 27.27%
  6. Cephalexin: 18 people, 27.27%
  7. Ibuprofen: 18 people, 27.27%
  8. Ativan: 18 people, 27.27%
  9. Percocet: 18 people, 27.27%
  10. Singulair: 17 people, 25.76%

Other side effects people have besides Hair loss *:

  1. Fatigue (feeling of tiredness): 29 people, 43.94%
  2. Weakness: 21 people, 31.82%
  3. Rashes (redness): 21 people, 31.82%
  4. Night Sweats (sweating in night): 18 people, 27.27%
  5. Hepatomegaly (abnormal enlargement of the liver): 18 people, 27.27%
  6. Hodgkin's Lymphoma (cancer originating from white blood cells): 18 people, 27.27%
  7. Keloids (overgrown scars left from skin injuries): 18 people, 27.27%
  8. Laryngocele (a congenital anomalous air sac communicating with the cavity of the larynx): 18 people, 27.27%
  9. Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung): 18 people, 27.27%
  10. Allergic Rhinitis: 17 people, 25.76%

* Approximation only. Some reports may have incomplete information.


How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

Drugs with ingredients of imiquimod, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on imiquimod. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: